Cargando…
Anti-cancer drug characterisation using a human cell line panel representing defined types of drug resistance.
Differential drug response in a human cell line panel representing defined types of cytotoxic drug resistance was measured using the non-clonogenic fluorometric microculture cytotoxicity assay (FMCA). In total 37 drugs were analysed; eight topoisomerase II inhibitors, eight anti-metabolites, eight a...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1996
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074735/ https://www.ncbi.nlm.nih.gov/pubmed/8826854 |
_version_ | 1782138031523758080 |
---|---|
author | Dhar, S. Nygren, P. Csoka, K. Botling, J. Nilsson, K. Larsson, R. |
author_facet | Dhar, S. Nygren, P. Csoka, K. Botling, J. Nilsson, K. Larsson, R. |
author_sort | Dhar, S. |
collection | PubMed |
description | Differential drug response in a human cell line panel representing defined types of cytotoxic drug resistance was measured using the non-clonogenic fluorometric microculture cytotoxicity assay (FMCA). In total 37 drugs were analysed; eight topoisomerase II inhibitors, eight anti-metabolites, eight alkylating agents, eight tubulin-active agents and five compounds with other or unknown mechanisms of action, including one topoisomerase I inhibitor. Correlation analysis of log IC50 values obtained from the panel showed a high degree of similarity among the drugs with a similar mechanism of action. The mean percentage of mechanistically similar drugs included among the ten highest correlations, when each drug was compared with the remaining data set, was 100%, 92%, 88% and 52% for the topoisomerase II inhibitors, alkylators, tubulinactive agents and anti-metabolites respectively. Classification of drugs into the four categories representing different mechanisms of action using a probabilistic neural network (PNN) analysis resulted in 29 (91%) correct predictions. The results indicate the feasibility of using a limited number of cell lines for prediction of mechanism of action of anti-cancer drugs. The present approach may be well suited for initial classification and evaluation of novel anti-cancer drugs and as a potential tool to guide lead compound optimisation. IMAGES: |
format | Text |
id | pubmed-2074735 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1996 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-20747352009-09-10 Anti-cancer drug characterisation using a human cell line panel representing defined types of drug resistance. Dhar, S. Nygren, P. Csoka, K. Botling, J. Nilsson, K. Larsson, R. Br J Cancer Research Article Differential drug response in a human cell line panel representing defined types of cytotoxic drug resistance was measured using the non-clonogenic fluorometric microculture cytotoxicity assay (FMCA). In total 37 drugs were analysed; eight topoisomerase II inhibitors, eight anti-metabolites, eight alkylating agents, eight tubulin-active agents and five compounds with other or unknown mechanisms of action, including one topoisomerase I inhibitor. Correlation analysis of log IC50 values obtained from the panel showed a high degree of similarity among the drugs with a similar mechanism of action. The mean percentage of mechanistically similar drugs included among the ten highest correlations, when each drug was compared with the remaining data set, was 100%, 92%, 88% and 52% for the topoisomerase II inhibitors, alkylators, tubulinactive agents and anti-metabolites respectively. Classification of drugs into the four categories representing different mechanisms of action using a probabilistic neural network (PNN) analysis resulted in 29 (91%) correct predictions. The results indicate the feasibility of using a limited number of cell lines for prediction of mechanism of action of anti-cancer drugs. The present approach may be well suited for initial classification and evaluation of novel anti-cancer drugs and as a potential tool to guide lead compound optimisation. IMAGES: Nature Publishing Group 1996-09 /pmc/articles/PMC2074735/ /pubmed/8826854 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Dhar, S. Nygren, P. Csoka, K. Botling, J. Nilsson, K. Larsson, R. Anti-cancer drug characterisation using a human cell line panel representing defined types of drug resistance. |
title | Anti-cancer drug characterisation using a human cell line panel representing defined types of drug resistance. |
title_full | Anti-cancer drug characterisation using a human cell line panel representing defined types of drug resistance. |
title_fullStr | Anti-cancer drug characterisation using a human cell line panel representing defined types of drug resistance. |
title_full_unstemmed | Anti-cancer drug characterisation using a human cell line panel representing defined types of drug resistance. |
title_short | Anti-cancer drug characterisation using a human cell line panel representing defined types of drug resistance. |
title_sort | anti-cancer drug characterisation using a human cell line panel representing defined types of drug resistance. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074735/ https://www.ncbi.nlm.nih.gov/pubmed/8826854 |
work_keys_str_mv | AT dhars anticancerdrugcharacterisationusingahumancelllinepanelrepresentingdefinedtypesofdrugresistance AT nygrenp anticancerdrugcharacterisationusingahumancelllinepanelrepresentingdefinedtypesofdrugresistance AT csokak anticancerdrugcharacterisationusingahumancelllinepanelrepresentingdefinedtypesofdrugresistance AT botlingj anticancerdrugcharacterisationusingahumancelllinepanelrepresentingdefinedtypesofdrugresistance AT nilssonk anticancerdrugcharacterisationusingahumancelllinepanelrepresentingdefinedtypesofdrugresistance AT larssonr anticancerdrugcharacterisationusingahumancelllinepanelrepresentingdefinedtypesofdrugresistance |